PIPAC is a laparoscopic ip chemotherapy delivery technique aiming to improve drug distribution and tissue penetration to treat peritoneal metastases. Intravenous (IV) nivolumab is approved for treatment of progressive gastric cancer after conventional chemotherapy. PIPAC in combination with nivolumab may impro...
To date, the only FDA (U.S. Food and Drug Administration)-approved therapies for advanced HCC patients include tyrosine kinase inhibitors (TKIs) and an immune checkpoint inhibitor, Nivolumab. TKIs, in general, could only extend the survival of HCC patients for about 3–6 months, whereas ...
FDA Grants Orphan Drug Designation to ELC-100 for Pancreatic NETsLatest Conference Coverage First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer Evorpacept Plus TRP Generates Superior Antitumor Responses, Survival Outcomes in HER2+ Gastric/GEJ Cancer First-Line...
Opdivo (nivolumab) is an immunotherapy used to treat a variety of cancer types, including melanoma. Durable responses to treatment have been observed following discontinuation of Opdivo therapy.Continue reading Related medical questions Drug information ...
One of the few GI cancers where immunotherapy has shown signs of making a difference is hepatocellular carcinoma (HCC), traditionally one of the most difficult cancers to treat. Since 2017, the PD-1 inhibitors pembrolizumab and nivolumab (Opdivo) have gained approvals as monotherapy in second-lin...
The best of National Geographic delivered to your inbox Sign up for more inspiring photos, stories, and special offers from National Geographic.Sign Up Legal Terms of Use Privacy Policy Interest-Based Ads Our Sites Nat Geo Home Attend a Live Event Book a Trip Buy Maps Inspire Your Kids Shop...
[9,10,13]. A major challenge related to SCLC is how to improve the clinical efficacy of its treatment. In addition, no survival benefit of nivolumab was observed in patients with chemo-resistant SCLC [14]. Clearly, there is a need to identify SCLC patients who might be sensitive to ...
. Chemotherapy doublet was compared with nivolumab alone in the PD-L1-positive group and nivolumab with chemo in the PD-L1-negative group. The third arm was nivo/ipi. As the study evolved, the sponsor company, Bristol-Myers Squibb, learned more about tumor mutational burden (TMB) as a ...
Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) constitute essential components of the TME.
Drug resistance is a major obstacle to treating cancers because it desensitizes cancer cells to chemotherapy. Recently, attention has been focused on changes in the tumor immune landscape after the acquisition of drug resistance. Programmed death-ligand-